Cytomegalovirus infection after bone marrow transplantation in children

被引:57
作者
Castagnola, E
Cappelli, B
Erba, D
Rabagliati, A
Lanino, E
Dini, G
机构
[1] G Gaslini Childrens Res Hosp, Dept Pediat Hematol & Oncol, I-16148 Genoa, Italy
[2] G Gaslini Childrens Res Hosp, Infect Dis Unit, I-16148 Genoa, Italy
[3] G Gaslini Childrens Res Hosp, Bone Marrow Transplant Unit, I-16148 Genoa, Italy
关键词
bone marrow transplant; hemopoietic stem cell transplant; graft versus host disease; human cytomegalovirus; pre-emptive therapy; transplant-related mortality;
D O I
10.1016/j.humimm.2004.02.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cytomegalovirus (CMV) is a well-known cause of disease occurring after bone marrow transplantation (BMT). The manifestations of CMV range from asymptomatic infection, defined as active CMV replication in the blood in the absence of clinical manifestations or organ failure abnormalities, to CMV disease, characterized by CMV infection with clinical symptoms or organ function abnormalities. Diagnostic procedures to assess the viral load have improved greatly with the increased use of antigenemia, CMV DNA, and immediate early-messenger RNA. Many conditions concur in determining the risk of developing CMV reactivation or disease after bone marrow transplant with serologic status of donor and recipient, type of bone marrow transplant, presence of graft-versus-host disease being the most studied. However, time and quality of immune reconstitution seems to be the pivotal factors. Pneumonia and gastrointestinal involvement are the most frequently documented clinical pictures with late-onset CMV reactivation or disease representing a new challenge. CMV prophylaxis or pre-emptive therapy adopted during the last few years in allogeneic BMT recipients has changed the natural history of the disease, reducing the risk of CMV disease, CMV-associated death, transplant - related mortality, and has prolonged the period at risk. Specific studies on children are lacking, however, the clinical pictures and features seems to be similar both in children and adults. Human Immunology 65, 416-422 (2004). (C) American Society for Histocompatibility and Immunogenetics, 2004. Published by Elsevier Inc.
引用
收藏
页码:416 / 422
页数:7
相关论文
共 52 条
[1]  
ADLER SP, 2002, PEDIAT INFECT DIS
[2]   Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance [J].
Bilgrami, S ;
Aslanzadeh, J ;
Feingold, JM ;
Bona, RD ;
Clive, J ;
Dorsky, D ;
Edwards, RL ;
Tutschka, PJ .
BONE MARROW TRANSPLANTATION, 1999, 24 (01) :69-73
[3]  
Boeckh M., 1996, Blood, V88, p302A
[4]   The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy [J].
Boeckh, M ;
Nichols, WG .
BLOOD, 2004, 103 (06) :2003-2008
[5]   Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity [J].
Boeckh, M ;
Leisenring, W ;
Riddell, SR ;
Bowden, RA ;
Huang, ML ;
Myerson, D ;
Stevens-Ayers, T ;
Flowers, MED ;
Cunningham, T ;
Corey, L .
BLOOD, 2003, 101 (02) :407-414
[6]   Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study [J].
Boeckh, M ;
Gooley, TA ;
Myerson, D ;
Cunningham, T ;
Schoch, G ;
Bowden, RA .
BLOOD, 1996, 88 (10) :4063-4071
[7]  
BOECKH MJ, 2002, TRANSPLANT INFECT
[8]   A COMPARISON OF FILTERED LEUKOCYTE-REDUCED AND CYTOMEGALOVIRUS (CMV) SERONEGATIVE BLOOD PRODUCTS FOR THE PREVENTION OF TRANSFUSION-ASSOCIATED CMV INFECTION AFTER MARROW TRANSPLANT [J].
BOWDEN, RA ;
SLICHTER, SJ ;
SAYERS, M ;
WEISDORF, D ;
CAYS, M ;
SCHOCH, G ;
BANAJI, M ;
HAAKE, R ;
WELK, K ;
FISHER, L ;
MCCULLOUGH, J ;
MILLER, W .
BLOOD, 1995, 86 (09) :3598-3603
[9]   Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation [J].
Broers, AEC ;
van der Holt, R ;
van Esser, JWJ ;
Gratama, JW ;
Henzen-Logmans, S ;
Kuenen-Boumeester, V ;
Löwenberg, B ;
Cornelissen, JJ .
BLOOD, 2000, 95 (07) :2240-2245
[10]   Survival after cytomegalovirus pneumonia in two children receiving autologous peripheral blood progenitor cell transplantation (PBPCT) [J].
Castagnola, E ;
Dallorso, S ;
Rabagliati, M ;
Sacco, O ;
Kotitsa, Z ;
Dini, G .
BONE MARROW TRANSPLANTATION, 1998, 21 (05) :529-531